HK Stock Market Move | REMGEN(09995) rose by over 7% again, the ophthalmic innovative drug RC28 applied for listing. It has previously reached a cooperation agreement with CanSino Biologics.

30/09/2025

Rong Chang Biology (09995) rose by over 7% again, as of the end of the reporting, it rose by 6.07% to HK$118.8, with a turnover of HK$476 million.

REMEGEN (09995) rose more than 7%, as of the time of writing, up 6.07% to 118.8 Hong Kong dollars, with a trading volume of 476 million Hong Kong dollars. On the news front, on September 30th, the CDE website showed that REMEGEN's ophthalmic innovative drug IluvienP (RC28) has applied for listing for the treatment of diabetic macular edema (DME). It is reported that in August of this year, REMEGEN reached an agreement with Santen Pharmaceutical's wholly-owned subsidiary Santen China to grant the exclusive development, production, and commercialization rights of IluvienP in Greater China, as well as Korea, Thailand, Vietnam, Singapore, the Philippines, Indonesia, and Malaysia, for a total transaction amount of 1.295 billion yuan. In addition, the 2025 European Society for Medical Oncology (ESMO) annual meeting will be held in Berlin, Germany, from October 17 to 21. Eleven original research results from REMEGEN have been successfully selected. Among them, the Phase III clinical research of Vedixitumab in combination therapy for first-line urinary tract urothelial carcinoma, RC48-C016, was selected for the latest breakthrough abstract (LBA). The company will also present the latest data for 10 different tumor types and related treatment strategies, including 2 short oral presentations and 8 poster presentations, covering areas such as urothelial carcinoma, gastric cancer, and gynecologic tumors.

HK Stock Market Move | Metallurgical Corporation of China (01618) rose more than 7%, institutions say the value of construction companies with abundant mineral resources urgently needs to be reassessed.

HK Stock Market Move | LAENA-B(02105) has risen by over 6% again, with a total increase of 36% over the past three trading days. The preliminary results of the LAE102 Phase I clinical MAD study are positive.

HK Stock Market Move | BOYAA (00434) rose more than 4% during trading. Recently established a strategic partnership with New Fire Technology, will deepen its presence in the Web3 field.